en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
3/2006
vol. 44
 
Share:
Share:
more
 
 
abstract:

Review Paper
B cell depletion with monoclonal antibody as treatment for rheumatoid arthritis

Piotr Wiland

RU 2006; 44, 3: 162–168
Online publish date: 2006/06/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
In recent years our knowledge of the role of B lymphocytes in the pathogenesis of rheumatoid arthritis (RA) has expanded and it is now thought that B cells have a more extensive role than was previously appreciated. They seem to play a pivotal role in the activation of synovial T cells and induction of cytokine secretion. CD20 antigen expressed on the surface of B cells is highly specific to B cells. The success of B cell depletion therapy by using the monoclonal antibody Rituximab, which targets CD20, further emphasized the importance of B cells in the pathogenesis of RA.
keywords:

rheumatoid arthritis, lymphocyte B, rituximab, CD20 antigen







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.